Back to News & Events

Intensity Therapeutics Awarded CRADA from National Cancer Institute

CFB Client Company, Intensity Therapeutics, Inc. established a cooperative research and development agreement (CRADA), with the National Institute of Health?s National Cancer Institute (NCI) Vaccine Branch. Intensity Therapeutics was awarded the CRADA by the NCI to study the efficacy and mechanism of action of Intensity?s in situ chemovaccination products using in vivo models of cancer. Read the full press release here.

Related Stories

No related post found.
This entry was posted in Uncategorized by admin. Bookmark the permalink.